<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493515</url>
  </required_header>
  <id_info>
    <org_study_id>UESTC-neuSCAN-69</org_study_id>
    <nct_id>NCT04493515</nct_id>
  </id_info>
  <brief_title>Oral Oxytocin's Effects on Attention Control</brief_title>
  <official_title>Oral Oxytocin's Effects on Attention Control: An Eye-tracking Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Electronic Science and Technology of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Electronic Science and Technology of China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of the study is to investigate whether orally administered oxytocin (24IU) could&#xD;
      modulate attention control using a social-emotional saccade/antisaccade eye-tracking&#xD;
      paradigm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous studies have reported the effect of intranasally administered oxytocin on&#xD;
      attentional processing including stimulus-driven bottom-up processing and top-down&#xD;
      goal-directed inhibitory control. However, it is unclear whether the functional effects are&#xD;
      mediated by the peptide directly entering the brain or indirectly via raising peripheral&#xD;
      concentrations. One possible method of producing a similar pattern of increased peripheral&#xD;
      oxytocin concentrations but without the possibility of direct entry into the brain would be&#xD;
      to administer the peptide lingually. In the present double-blind, between-subject,&#xD;
      placebo-controlled study, 80 healthy male subjects will be recruited and receive either&#xD;
      oxytocin (24IU) or placebo control administered orally (lingual). 45 minutes after treatment&#xD;
      subjects are required to complete a social-emotional saccade/antisaccade eye-tracking&#xD;
      paradigm. This paradigm uses social (happy, sad, angry, fear, and neutral faces) as well as&#xD;
      non-social (oval shapes) stimuli to explore social- and emotion-specific effects of orally&#xD;
      administered oxytocin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Between-subject randomized placebo-controlled double-blind pharmacological eye-tracking design</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of oral oxytocin administration on saccade/antisaccade latencies towards social (facial) versus non-social (shape) stimuli</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between social-specific saccade/antisaccade latencies (in milliseconds) between the oxytocin and placebo treatment conditions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of oral oxytocin administration on error rates of saccade/antisaccade for social (facial) versus non-social (shape) stimuli</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between social-specific error rates of saccade/antisaccade between the oxytocin and placebo treatment conditions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Emotion-specific effects of oral oxytocin administration on saccade/antisaccade latencies towards the separate facial emotions</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between emotion-specific saccade/antisaccade latencies (in milliseconds) between the oxytocin and placebo treatment conditions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emotion-specific effects of oral oxytocin administration on saccade/antisaccade error rates for the separate facial emotions</measure>
    <time_frame>45 minutes - 100 minutes after treatment</time_frame>
    <description>Comparison between emotion-specific saccade/antisaccade error rates between the oxytocin and placebo treatment conditions</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin orally (24 IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orally (24 IU, identical ingredients, except the active agent)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Oxytocin</intervention_name>
    <description>Administration of oxytocin orally (24 IU)</description>
    <arm_group_label>Oral Oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Placebo</intervention_name>
    <description>Administration of placebo orally (24 IU)</description>
    <arm_group_label>Oral Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male, healthy participants&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current medical, psychiatric, neurological disorder&#xD;
&#xD;
          -  Regular medication&#xD;
&#xD;
          -  Use of any psychoactive substances in the 24 hours before experiment&#xD;
&#xD;
          -  Contra-indications for oxytocin&#xD;
&#xD;
          -  Contra-indications for eye-tracking data acquisition&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Keith Kendrick, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Electronic Science and Technology of China (UESTC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhuang Qian, MD</last_name>
    <phone>13086663679</phone>
    <email>zq19910362@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xu Xiaolei, PhD</last_name>
    <phone>18780140034</phone>
    <email>rabby_uestc@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Electronic Science and Technology of China(UESTC)</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>611731</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Weihua, PhD</last_name>
      <phone>+86 2861 830 811</phone>
      <email>zarazhao.uestc@outlook.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 27, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Electronic Science and Technology of China</investigator_affiliation>
    <investigator_full_name>Keith Kendrick</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

